• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一名年轻成年男性非功能性囊性垂体腺瘤对卡麦角林反应的特殊病例

A Peculiar Case of Cabergoline Response to a Non-functioning Cystic Pituitary Adenoma in a Young Adult Male.

作者信息

Rahman Austin, Piasecki Joshua, Rogers Patrick, Koo David

机构信息

Emergency Medicine, Lake Erie College of Osteopathic Medicine, Bradenton, USA.

Medical School, Lake Erie College of Osteopathic Medicine, Bradenton, USA.

出版信息

Cureus. 2024 Aug 27;16(8):e67927. doi: 10.7759/cureus.67927. eCollection 2024 Aug.

DOI:10.7759/cureus.67927
PMID:39221401
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11365584/
Abstract

We present an interesting case of a cystic, pituitary adenoma that showed up insidiously with non-traditional clinical symptoms. The standard of care for non-functioning pituitary adenomas is transsphenoidal surgery. However, with pharmacotherapy using cabergoline (a dopamine receptor agonist), the patient had a near disappearance of the tumor. This case report seeks to add to the medical literature the possibility of pharmacotherapy for treating non-functional pituitary adenomas.

摘要

我们报告了一例有趣的囊性垂体腺瘤病例，该病例以非传统临床症状隐匿出现。无功能性垂体腺瘤的标准治疗方法是经蝶窦手术。然而，通过使用卡麦角林（一种多巴胺受体激动剂）进行药物治疗，患者的肿瘤几乎消失。本病例报告旨在为医学文献增添药物治疗无功能性垂体腺瘤的可能性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2851/11365584/57291ae9b191/cureus-0016-00000067927-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2851/11365584/55a53a873565/cureus-0016-00000067927-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2851/11365584/57291ae9b191/cureus-0016-00000067927-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2851/11365584/55a53a873565/cureus-0016-00000067927-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2851/11365584/57291ae9b191/cureus-0016-00000067927-i02.jpg

相似文献

1
A Peculiar Case of Cabergoline Response to a Non-functioning Cystic Pituitary Adenoma in a Young Adult Male.一名年轻成年男性非功能性囊性垂体腺瘤对卡麦角林反应的特殊病例
Cureus. 2024 Aug 27;16(8):e67927. doi: 10.7759/cureus.67927. eCollection 2024 Aug.
2
In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas.临床无功能垂体腺瘤患者的体内分泌潜能及奥曲肽与卡麦角林联合治疗的效果
Clin Endocrinol (Oxf). 2001 Jan;54(1):23-30. doi: 10.1046/j.1365-2265.2001.01172.x.
3
Gonadotroph adenoma with secondary hypersecretion of testosterone.促性腺激素腺瘤伴睾丸酮的继发性分泌过多。
World Neurosurg. 2013 Dec;80(6):900.e7-11. doi: 10.1016/j.wneu.2012.11.069. Epub 2012 Nov 28.
4
Effects of cabergoline in a pituitary adenoma secreting follicle-stimulating hormone.卡麦角林对分泌促卵泡激素的垂体腺瘤的影响。
Postgrad Med J. 1997 Aug;73(862):507-8. doi: 10.1136/pgmj.73.862.507.
5
Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.分泌催乳素和临床无功能垂体腺瘤患者中激素水平及肿瘤大小对喹高利特和卡麦角林的反应：123I-甲氧基苄胺垂体闪烁显像的预测价值
Clin Endocrinol (Oxf). 2000 Apr;52(4):437-45. doi: 10.1046/j.1365-2265.2000.00951.x.
6
Abnormal response of luteinizing hormone beta subunit to thyrotrophin-releasing hormone in patients with non-functioning pituitary adenoma.无功能垂体腺瘤患者促黄体生成素β亚基对促甲状腺激素释放激素的异常反应。
Clin Endocrinol (Oxf). 1994 Nov;41(5):661-6. doi: 10.1111/j.1365-2265.1994.tb01833.x.
7
Co-occurrence of Functional Gonadotroph Adenoma and Lactotroph Adenoma: A Case Report and Literature Review.功能性促性腺激素腺瘤与催乳素细胞腺瘤并存：一例报告及文献复习
AACE Clin Case Rep. 2022 Nov 5;9(1):5-9. doi: 10.1016/j.aace.2022.11.001. eCollection 2023 Jan-Feb.
8
Cabergoline modulation of alpha-subunits and FSH secretion in a gonadotroph adenoma.卡麦角林对促性腺激素腺瘤中α亚基和促卵泡激素分泌的调节作用
J Endocrinol Invest. 2000 Jul-Aug;23(7):463-6. doi: 10.1007/BF03343756.
9
A clinically functioning gonadotroph adenoma presenting with abdominal pain, ovarian hyperstimulation and fibromatosis.一例表现为腹痛、卵巢过度刺激和纤维瘤病的具有临床功能的促性腺激素腺瘤。
Endocrinol Diabetes Metab Case Rep. 2018;2018. doi: 10.1530/EDM-18-0123. Epub 2018 Dec 11.
10
Non-functioning pituitary adenomas.无功能垂体腺瘤
J Endocrinol Invest. 2005;28(11 Suppl International):93-9.

本文引用的文献

1
Diagnosis and Management of Pituitary Adenomas: A Review.垂体腺瘤的诊断与管理：综述
JAMA. 2023 Apr 25;329(16):1386-1398. doi: 10.1001/jama.2023.5444.
2
Pituitary Adenomas: From Diagnosis to Therapeutics.垂体腺瘤：从诊断到治疗
Biomedicines. 2021 Apr 30;9(5):494. doi: 10.3390/biomedicines9050494.
3
The Epidemiology of Pituitary Adenomas.《垂体腺瘤的流行病学》
Endocrinol Metab Clin North Am. 2020 Sep;49(3):347-355. doi: 10.1016/j.ecl.2020.04.002. Epub 2020 Jun 10.
4
Functioning Pituitary Adenomas - Current Treatment Options and Emerging Medical Therapies.功能性垂体腺瘤——当前的治疗选择与新兴药物疗法
Eur Endocrinol. 2019 Apr;15(1):30-40. doi: 10.17925/EE.2019.15.1.30. Epub 2019 Apr 12.
5
Diagnosis and Treatment of Pituitary Adenomas: A Review.垂体腺瘤的诊断与治疗：综述
JAMA. 2017 Feb 7;317(5):516-524. doi: 10.1001/jama.2016.19699.
6
Differentiation between Cystic Pituitary Adenomas and Rathke Cleft Cysts: A Diagnostic Model Using MRI.囊性垂体腺瘤与拉克氏裂囊肿的鉴别：一种使用MRI的诊断模型
AJNR Am J Neuroradiol. 2015 Oct;36(10):1866-73. doi: 10.3174/ajnr.A4387. Epub 2015 Aug 6.
7
Hyperprolactinemia and infertility: new insights.高泌乳素血症与不孕：新的认识。
J Clin Invest. 2012 Oct;122(10):3467-8. doi: 10.1172/jci64455.
8
Silent corticotroph adenomas: Emory University cohort and comparison with ACTH-negative nonfunctioning pituitary adenomas.无功能垂体腺瘤中静默促肾上腺皮质激素腺瘤：埃默里大学队列研究及与 ACTH 阴性无功能垂体腺瘤的比较。
Neurosurgery. 2012 Aug;71(2):296-303; discussion 304. doi: 10.1227/NEU.0b013e318257c1f0.
9
Clinically silent somatotroph adenomas are common.临床上无功能的生长激素腺瘤很常见。
Eur J Endocrinol. 2011 Jul;165(1):39-44. doi: 10.1530/EJE-11-0216. Epub 2011 Apr 14.
10
Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline.高泌乳素血症的诊断和治疗：内分泌学会临床实践指南。
J Clin Endocrinol Metab. 2011 Feb;96(2):273-88. doi: 10.1210/jc.2010-1692.